(Q33439829)

English

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

pancreatic carcinoma

1 reference

based on heuristic

inferred from title

0 references

0 references

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

David Cunningham

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Srinivasan Madhusudan

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Eithne Costello

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

John P Neoptolemos

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

6

object named as

Trevor Cox

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Victoria E Shaw

8

object named as

Victoria E Shaw

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

William Greenhalf

3

object named as

William Greenhalf

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1

object named as

Gary Middleton

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

4

object named as

Paula Ghaneh

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Jonathan Wadsley

9

object named as

Jonathan Wadsley

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

11

object named as

David Propper

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

13

object named as

Stephen Falk

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

15

object named as

Fareeda Coxon

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

18

object named as

Nick Wadd

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

19

object named as

Pippa Corrie

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Charlotte L Rawcliffe

23

object named as

Charlotte Rawcliffe

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

author name string

Daniel H Palmer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Richard Jackson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Juan W Valle

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Harpreet Wasan

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Paul Ross

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Tamas Hickish

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Fiona Campbell

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

publication date

2 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

486-499

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

describes a project that uses

phase II clinical trial

0 references

0 references

multicenter clinical trial

0 references

immunohistochemistry

0 references

Kaplan–Meier estimator

0 references

Common Terminology Criteria for Adverse Events

0 references

0 references

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

RET revisited: expanding the oncogenic portfolio

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930084-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30084-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28259610%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33439829&oldid=1744021605"